Dissecting the antibody constant region protective immune parameters in HIV infection

Future Virology

Volumn 9, Issue 4, 2014, Pages 397-414

  Chung, Amy W ^a   Alter, Galit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ADCC; antibody; antibody dependent cellular phagocytosis; antibody dependent cellular viral inhibition; antibody dependent complement dependent cytotoxicity; Fc; Fc effector function; glycosylation; HIV; IgG; subclass

Indexed keywords

COMPLEMENT; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN SUBCLASS; RV144 VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CONFORMATIONAL TRANSITION; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION;

EID: 84900003088     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.19     Document Type: Review

References (150)

1. Hammer SM, Sobieszczyk ME, Janes H et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083-2092 (2013).
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
3. Haynes BF, Gilbert PB, Mcelrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1286 (2012).
4. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100(7), 4144-4149 (2003).
5. Mccoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210(2), 209-223 (2013).
6. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5(2), 204-210 (1999).
7. Kohl S. Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus. Rev. Infect. Dis. 13(Suppl. 11), S950-S952 (1991).
8. Yoneto T, Waki S, Takai T et al. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J. Immunol. 166(10), 6236-6241 (2001).
9. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30(7), 356-362 (2009).
10. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8(1), 34-47 (2008).
11. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr. HIV Res. 6(6), 515-519 (2008).
12. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol. Today 12(9), 322-326 (1991).
13. Dugast AS, Tonelli A, Berger CT et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 415(2), 160-167 (2011).
14. Yu Q, Yu R, Qin X. The good and evil of complement activation in HIV-1 infection. Cell. Mol. Immunol. 7(5), 334-340 (2010).
15. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4(5), 388-393 (2009).
16. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 17(1), 107-115 (2002).
17. Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS ONE 8(10), e76176 (2013).
18. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526(2), 159-166 (2012).
19. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S41-S52 (2010).
20. Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol. 4(6), 590-597 (2011).
21. Zhang M, Murphy RF, Agrawal DK. Decoding IgE Fc receptors. Immunol. Res. 37(1), 1-16 (2007).
22. Choi SC, Wang H, Tian L et al. Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates antigen-driven immune responses. J. Immunol. 190(3), 987-996 (2013).
23. Klimovich VB. IgM and its receptors: structural and functional aspects. Biochemistry (Mosc. ) 76(5), 534-549 (2011).
24. Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand. J. Immunol. 52(3), 240-248 (2000).
25. Czajkowsky DM, Salanti A, Ditlev SB et al. IgM, Fc mu Rs, and malarial immune evasion. J. Immunol. 184(9), 4597-4603 (2010).
26. Kikuno K, Kang DW, Tahara K et al. Unusual biochemical features and follicular dendritic cell expression of human Fcalpha/ mu receptor. Eur. J. Immunol. 37(12), 3540-3550 (2007).
27. Honda S, Kurita N, Miyamoto A et al. Enhanced humoral immune responses against T-independent antigens in Fc alpha/ muR-deficient mice. Proc. Natl Acad. Sci. USA 106(27), 11230-11235 (2009).
28. Shibuya A, Sakamoto N, Shimizu Y et al. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol. 1(5), 441-446 (2000).
29. Kubagawa H, Oka S, Kubagawa Y et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J. Exp. Med. 206(12), 2779-2793 (2009).
30. Czajkowsky DM, Shao Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc. Natl Acad. Sci. USA 106(35), 14960-14965 (2009).
31. Van De Perre P, Desgranges C, Burny A. IgM antibodies directed to HIV: the neglected issue? AIDS Res. Hum. Retroviruses 10(5), 517-520 (1994).
32. Van De Perre P, Simonon A, Hitimana DG et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet 341(8850), 914-918 (1993).
33. Ogundele M. Role and significance of the complement system in mucosal immunity: particular reference to the human breast milk complement. Immunol. Cell Biol. 79(1), 1-10 (2001).
34. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Ann. Rev. Immunol. 17, 931-972 (1999).
35. Karagiannis SN, Bracher MG, Hunt J et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J. Immunol. 179(5), 2832-2843 (2007).
36. Karagiannis SN, Josephs DH, Karagiannis P et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol. Immunother. 61(9), 1547-1564 (2012).
37. Rudman SM, Josephs DH, Cambrook H et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FceRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin. Exp. Allergy 41(10), 1400-1413 (2011).
38. Ravetch JV, Kinet JP. Fc receptors. Ann. Rev. Immunol. 9, 457-492 (1991).
39. Marone G, Florio G, Petraroli A, De Paulis A. Dysregulation of the IgE/Fc epsilon RI network in HIV-1 infection. J. Allergy Clin. Immunol. 107(1), 22-30 (2001).
40. Marone G, Florio G, Petraroli A, Triggiani M, De Paulis A. Role of human FcepsilonRI+ cells in HIV-1 infection. Immunol. Rev. 179, 128-138 (2001).
41. Blackard JT. HIV compartmentalization: a review on a clinically important phenomenon. Curr. HIV Res. 10(2), 133-142 (2012).
42. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit. Rev. Oncol. Hematol. 39(1-2), 69-77 (2001).
43. Corthesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J. Immunol. 178(1), 27-32 (2007).
44. Fujioka H, Emancipator SN, Aikawa M et al. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. J. Exp. Med. 188(7), 1223-1229 (1998).
45. Bakema JE, Van Egmond M. The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 4(6), 612-624 (2011).
46. Valerius T, Stockmeyer B, Van Spriel AB et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90(11), 4485-4492 (1997).
47. Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J. Clin. Invest. 104(8), 1139-1147 (1999).
48. Renegar KB, Jackson GD, Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J. Immunol. 160(3), 1219-1223 (1998).
49. Boross P, Lohse S, Nederend M et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol. Med. 5(8), 1213-1226 (2013).
50. Huls G, Heijnen IA, Cuomo E et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 59(22), 5778-5784 (1999).
51. Ben Mkaddem S, Rossato E, Heming N, Monteiro RC. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun. Rev. 12(6), 666-669 (2013).
52. Mattu TS, Pleass RJ, Willis AC et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcalpha receptor interactions. J. Biol. Chem. 273(4), 2260-2272 (1998).
53. Gomes MM, Wall SB, Takahashi K, Novak J, Renfrow MB, Herr AB. Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding. Biochemistry 47(43), 11285-11299 (2008).
54. Tomaras GD, Ferrari G, Shen X et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA 110(22), 9019-9024 (2013).
55. Black KP, Cummins JE Jr, Jackson S. Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity. Clin. Immunol. Immunopathol. 81(2), 182-190 (1996).
56. Broliden K, Hinkula J, Devito C et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 79(1-2), 29-36 (2001).
57. Hirbod T, Kaul R, Reichard C et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22(6), 727-735 (2008).
58. Dorrell L, Hessell AJ, Wang M et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 14(9), 1117-1122 (2000).
59. Watkins JD, Sholukh AM, Mukhtar MM et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27(9), F13-F20 (2013).
60. Wolff H, Mayer K, Seage G, Politch J, Horsburgh CR, Anderson D. A comparison of HIV-1 antibody classes, titers, and specificities in paired semen and blood samples from HIV-1 seropositive men. J. Acquir. Immune Defic. Syndr. 5(1), 65-69 (1992).
61. Muller F, Froland SS, Hvatum M, Radl J, Brandtzaeg P. Both IgA subclasses are reduced in parotid saliva from patients with AIDS. Clin. Exp. Immunol. 83(2), 203-209 (1991).
62. Papadea C, Check IJ. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit. Rev. Clin. Lab. Sci. 27(1), 27-58 (1989).
63. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1), 17-23 (2012).
64. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol. Today 16(2), 85-90 (1995).
65. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6(11), 1161-1173 (2006).
66. Julien JP, Sok D, Khayat R et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9(5), e1003342 (2013).
67. Goh YS, Grant AJ, Restif O et al. Human IgG isotypes and activating Fcgamma receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology 133(1), 74-83 (2011).
68. Salfeld JG. Isotype selection in antibody engineering. Nat. Biotechnol. 25(12), 1369-1372 (2007).
69. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63(1), 127-134 (1986).
70. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J. Immunol. 170(6), 3134-3138 (2003).
71. Mrabet-Dahbi S, Breuer K, Klotz M et al. Deficiency in immunoglobulin G2 antibodies against staphylococcal enterotoxin C1 defines a subgroup of patients with atopic dermatitis. Clin. Exp. Allergy 35(3), 274-281 (2005).
72. Van Der Neut Kolfschoten M, Schuurman J, Losen M et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317(5844), 1554-1557 (2007).
73. Karagiannis P, Gilbert AE, Josephs DH et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 123(4), 1457-1474 (2013).
74. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr. Opin. Rheumatol. 23(1), 119-124 (2011).
75. Banerjee K, Klasse PJ, Sanders RW et al. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 26(4), 445-458 (2010).
76. Yates NL, Lucas JT, Nolen TL et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 25(17), 2089-2097 (2011).
77. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin. Exp. Immunol. 73(3), 343-347 (1988).
78. Forthal DN, Landucci G, Ding H et al. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 25(17), 2099-2104 (2011).
79. Chung AW, Ghebremichael M, Robinson H. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003. Sci. Trans. Med. 6(228), 228ra38 (2014).
80. Grodeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS ONE 8(11), e80008 (2013).
81. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8(3), 226-234 (2009).
82. Hristodorov D, Fischer R, Linden L. With or without sugar? (A)glycosylation of therapeutic antibodies. Mol. Biotechnol. 54(3), 1056-1068 (2013).
83. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30), 26733-26740 (2002).
84. Routier FH, Hounsell EF, Rudd PM et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J. Immunol. Methods 213(2), 113-130 (1998).
85. Dall'olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-glycomic biomarkers of biological aging and longevity: a link with inflammaging. Ageing Res. Rev. 12(2), 685-698 (2013).
86. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N -glycan remodeling in vitro. Biotechnol. Prog. 21(6), 1644-1652 (2005).
87. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1(3), 237-243 (1995).
88. Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies Hybridomas 5(3-4), 143-151 (1994).
89. Kumpel BM, Wang Y, Griffiths HL, Hadley AG, Rook GA. The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum. Antibodies Hybridomas 6(3), 82-88 (1995).
90. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32(17-18), 1311-1318 (1995).
91. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N -acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(5), 3466-3473 (2003).
92. Peipp M, Lammerts Van Bueren JJ, Schneider- Merck T et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6), 2390-2399 (2008).
93. Niwa R, Natsume A, Uehara A et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306(1-2), 151-160 (2005).
94. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17(2), 176-180 (1999).
95. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4- N -acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 93(5), 851-861 (2006).
96. Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX. Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J. Am. Chem. Soc. 133(46), 18975-18991 (2011).
97. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787), 670-673 (2006).
98. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30(Suppl. 1), S9-S14 (2010).
99. Scallon BJ, Tam SH, Mccarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44(7), 1524-1534 (2007).
100. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105(50), 19571-19578 (2008).
101. Pound JD, Lund J, Jefferis R. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol. Immunol. 30(3), 233-241 (1993).
102. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J. Immunol. 190(8), 4315-4323 (2013).
103. Ackerman ME, Crispin M, Yu X et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123(5), 2183-2192 (2013).
104. Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23(8), 897-906 (2009).
105. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol. Suppl. 67, 5-14 (2007).
106. Mahan A, Tedesco J, Dionne K et al. Antibody glycosylation can be transiently altered after vaccination against HIV. Presented at: AIDS Vaccine. Barcelona, Spain, 7-10 October 2013.
107. Campbell CT, Llewellyn SR, Damberg T, Morgan IL, Robert-Guroff M, Gildersleeve JC. High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge. PLoS ONE 8(9), e75302 (2013).
108. Leu RW, Robinson CJ, Wiggins JA, Shannon BJ, Rummage JA, Horn MJ. Photometric assays for FcRI-dependent binding, phagocytosis, and antibody-dependent cellular cytotoxicity mediated by monomeric IgG gamma 2a in murine peritoneal macrophages. J. Immunol. Methods 113(2), 269-278 (1988).
109. Van De Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 49(5), 511-524 (1991).
110. Ceuppens JL, Baroja ML, Van Vaeck F, Anderson CL. Defect in the membrane expression of high affinity 72-kD Fc gamma receptors on phagocytic cells in four healthy subjects. J. Clin. Invest. 82(2), 571-578 (1988).
111. Zhang CY, Booth JW. Differences in endocytosis mediated by FcgammaRIIA and FcgammaRIIB2. Mol. Immunol. 49(1-2), 329-337 (2011).
112. Nimmerjahn F, Ravetch JV. Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol. 415, 151-162 (2008).
113. Baerenwaldt A, Lux A, Danzer H et al. Fcgamma receptor IIB (FcgammaRIIB) maintains humoral tolerance in the human immune system in vivo. Proc. Natl Acad. Sci. USA 108(46), 18772-18777 (2011).
114. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189(1), 179-185 (1999).
115. Gergely J, Pecht I, Sarmay G. Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunol. Lett. 68(1), 3-15 (1999).
116. Pricop L, Redecha P, Teillaud JL et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166(1), 531-537 (2001).
117. Tabb B, Morcock DR, Trubey CM et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J. Invest. Dis. 207(6), 880-892 (2013).
118. Miedema F, Hazenberg MD, Tesselaar K, Van Baarle D, De Boer RJ, Borghans JA. Immune activation and collateral damage in AIDS pathogenesis. Front. Immunol. 4, 298 (2013).
119. Willcocks LC, Carr EJ, Niederer HA et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107(17), 7881-7885 (2010).
120. Hatjiharissi E, Xu L, Santos DD et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110(7), 2561-2564 (2007).
121. Poonia B, Kijak GH, Pauza CD. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS ONE 5(12), e15562 (2010).
122. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 120(14), 2836-2842 (2012).
123. Maeda M, Van Schie RC, Yuksel B et al. Differential expression of Fc receptors for IgG by monocytes and granulocytes from neonates and adults. Clin. Exp. Immunol. 103(2), 343-347 (1996).
124. Capsoni F, Minonzio F, Ongari AM et al. Increased expression of IgG Fc receptor type I on neutrophils and monocytes from HIV-infected subjects. Clin. Exp. Immunol. 90(2), 175-180 (1992).
125. Hunter S, Indik ZK, Kim MK, Cauley MD, Park JG, Schreiber AD. Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor. Blood 91(5), 1762-1768 (1998).
126. Anegon I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167(2), 452-472 (1988).
127. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202(7), 1001-1012 (2005).
128. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101-104 (2007).
129. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 10(2), 258-266 (1996).
130. Baum LL, Cassutt KJ, Knigge K et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157(5), 2168-2173 (1996).
131. Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 24(2), 171-175 (2011).
132. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75(15), 6953-6961 (2001).
133. Ahmad R, Sindhu ST, Toma E et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21(3), 227-233 (2001).
134. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178(10), 6596-6603 (2007).
135. Forthal DN, Landucci G, Haubrich R et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180(4), 1338-1341 (1999).
136. Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. (2011).
137. Weiner GJ. Rituximab: mechanism of action. Semin. Hematol. 47(2), 115-123 (2010).
138. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 24(4), 487-499 (2005).
139. Barouch DH, Stephenson KE, Borducchi EN et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155(3), 531-539 (2013).
140. Moldt B, Shibata-Koyama M, Rakasz EG et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86(11), 6189-6196 (2012).
141. Huber M, Fischer M, Misselwitz B et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 3(11), e441 (2006).
142. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/ macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J. Clin. Virol. 26(2), 247-263 (2003).
143. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179(11), 7916-7923 (2007).
144. Zhu P, Chertova E, Bess J Jr et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl Acad. Sci. USA 100(26), 15812-15817 (2003).
145. Chung AW, Isitman G, Navis M et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl Acad. Sci. USA 108(18), 7505-7510 (2011).
146. Wren LH, Chung AW, Isitman G et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138(2), 116-123 (2013).
147. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412(1), 110-116 (2011).
148. Grunow R, Franke L, Hinkula J et al. Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro. Clin. Diagn. Virol. 3(3), 221-231 (1995).
149. Bonsignori M, Pollara J, Moody MA et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86(21), 11521-11532 (2012).
150. Gottardo R, Bailer RT, Korber BT et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 8(9), e75665 (2013).